TCCL Archive Individualized Cancer Vaccines Show 90% Survival at 6 Months December 27, 2013Vol.36 No.12
TCCL Archive Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial December 27, 2013Vol.36 No.12
TCCL Archive Two Phase II Studies of Ibrutinib Deliver High Response Rates December 27, 2013Vol.36 No.12
TCCL Archive NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent December 27, 2013Vol.36 No.12
TCL Archive Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival November 29, 2013Vol.36 No.11
TCL Archive Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response November 29, 2013Vol.36 No.11
